Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2002 Jan 26;324(7331):226-9.
doi: 10.1136/bmj.324.7331.226.

First trial of the HIV-1 vaccine in Africa: Ugandan experience

Roy D Mugerwa  1 , Pontiano Kaleebu, Peter Mugyenyi, Edward Katongole-Mbidde, David L Hom, Rose Byaruhanga, Robert A Salata, Jerrold J Ellner; HIV-1 Vaccine Trial Group
Affiliations
Review

First trial of the HIV-1 vaccine in Africa: Ugandan experience

Roy D Mugerwa et al. BMJ. .
No abstract available

PubMed Disclaimer

Figures

Figure
Figure
Election posters for President Museveni of Uganda, who was accused of sanctioning the use of a trial HIV vaccine on Ugandans in exchange for money to finance war in the Congo
Figure
Figure
Estimated number of people living with HIV and AIDS in Uganda at the end of 1999. Data from UNAIDS/WHO epidemiological fact sheet on HIV/AIDS and sexually transmitted infections. Uganda. 2000 update
Figure
Figure
Proportion of people reporting use of condom during most recent “intercourse of risk” (left) and proportion of sexually active people having at least one sexual partner other than their regular partner in the past 12 months (right) in rural and urban areas of Uganda in 1995. Data from UNAIDS/WHO epidemiological fact sheet on HIV/AIDS and sexually transmitted infections. Uganda. 2000 update
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Esparza J, Bhamarapravati N. Accelerating the development and future availability of HIV-1 vaccines: why, when, where, and how. Lancet. 2000;355:2061–2066. - PubMed
    1. Kebba A, Hom DL, Mugyenyi P, Salata R, Mbidde E, Kaleebu P, et al. Phase I vaccine study of the ALVAC-HIV vCP205 in healthy Ugandan adults [abstract]. XIII International Conference on AIDS, Durban, South Africa, July 9-14, 2000.
    1. Salmon-Ceron D, Excler JL, Finkielsztejn L, Autran B, Gluckman JC, Sicard D, et al. Safety and immunogenicity of a live recombinant canarypox virus expressing HIV type 1 gp120 MN MN tm/gag/protease LAI (ALVAC-HIV, vCP 205) followed by a p24E-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV infection. AIDS Res Hum Retrovir. 1999;15:633–645. - PubMed
    1. Lurie P, Bishaw M, Chesney MA, Cooke M, Fernandes ME, Hearst N, et al. Ethical, behavioural, and social aspects of HIV vaccine trials in developing countries. JAMA. 1994;271:295–301. - PubMed
    1. Temoshok LR. Behavioral research contributions to planning and conducting HIV vaccine efficacy studies. AIDS Res Hum Retroviruses. 1994;10 (Suppl 2):S277–S280. - PubMed

Publication types